Other non-invasive emerging biomarkers aimed to differentiate NASH from simple steatosis include proinflammatory cytokines (e.g., CXCL10, TNFα, IL-8), iron metabolism markers (e.g., serum iron, ferritin) and hormones (e.g., FGF21, adiponectin, leptin, resistin) [12]. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.